Breanna O’Reilly, PhD

Breanna is an Analyst on the Investment Team at RA Capital Management, where she invests in late-stage private and public biotechnology companies and advises RA Capital’s portfolio companies on program and pipeline strategy. As an Associate at RA Capital, she covered immunology, hematologic oncology, rare and genetic diseases, and neuropsychology. Prior to RA Capital, Breanna was a postdoctoral associate at Howard Hughes Medical Institute. Breanna currently serves as a board observer at CellCentric. Dr. O’Reilly holds a BS in Biomedical Engineering from the University of Rochester and a PhD in Biomedical Engineering from Boston University.